Core Viewpoint - Multiple companies indicate that their brain-computer interface (BCI) products are still in the early cultivation stage, with significant differences in technical routes compared to international mainstream technologies [1]. Group 1: Company Announcements - Several listed companies, including Nanjing Mailande Medical Technology Co., Ltd., reported that their BCI products are still in the research and market cultivation phase and have not yet achieved large-scale sales, thus not significantly impacting their financial performance [4][5]. - Mailande focuses on the development and productization of non-invasive BCI technology, which differs significantly from the invasive BCI technologies currently mainstream internationally [4]. - Weisi Medical also stated that its new products in the BCI field are in the early market cultivation stage, primarily focusing on non-invasive technology, with limited contribution to overall revenue [5]. - Xiangyu Medical revealed that it is concentrating on non-invasive BCI technology, covering various rehabilitation scenarios, but has not yet achieved large-scale sales, resulting in a small revenue contribution [8]. Group 2: Market Reactions and Regulatory Actions - As of January 6, several BCI-related stocks experienced a cumulative price deviation exceeding 30% over three consecutive trading days, prompting the companies to issue announcements regarding abnormal stock trading [4]. - The Shanghai Stock Exchange issued an inquiry letter to Yahui Long, requesting additional disclosures regarding its strategic cooperation framework agreement with Shenzhen Brain Machine Star Chain Technology Co., Ltd., including details on technology routes and product types [11]. - Yahui Long's subsequent announcement clarified that its partner, Brain Machine Star Chain, is in the early stages of product development, focusing on non-invasive technologies, and has not yet entered the registration phase for its products [13].

证券时报·数据宝统计显示，佰仁医疗今日收盘价为110.04元，下跌0.29%，日换手率为0.29%，成交额 为4334.77万元，全天主力资金净流出124.44万元，近5日该股累计下跌0.88%，近5日资金合计净流出 2948.02万元。 两融数据显示，该股最新融资余额为2.91亿元，近5日增加988.67万元，增幅为3.51%。（数据宝） 1月6日佰仁医疗大宗交易一览 | 成交量 | 成交金额 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | （万 | （万元） | 格 | 折溢价（%） | 买方营业部 | 卖方营业部 | | 股） | | （元） | | | | | 5.27 | 579.91 | 110.04 | 0.00 | 华鑫证券有限责任公司上 | 招商证券股份有限公司上 | | | | | | 海景东路证券营业部 | 海世纪大道证券营业部 | （文章来源：证券时报网） 佰仁医疗1月6日大宗交易平台出现一笔成交，成交量5.27万股，成交金额579.91万元，大宗交易成交价 为110.04元。该笔交易的买方营业部为华鑫证券有限责 ...

| 买入营业部名称 | 买入金额(万元) | | --- | --- | | 机构专用 | 3499.05 | | 国泰海通证券股份有限公司深圳人民南路证券营业部 | 2643.39 | | 中信建投证券股份有限公司河北分公司 | 2447.71 | | 华泰证券股份有限公司深圳彩田路证券营业部 | 1874.41 | | 广发证券股份有限公司郑州农业路证券营业部 | 1849.82 | | 卖出营业部名称 | 卖出金额(万元) | | 第一创业证券股份有限公司杭州分公司 | 2065.72 | | 南京证券股份有限公司南京江东中路证券营业部 | 1785.03 | | 中国银河证券股份有限公司广州琶洲大道证券营业部 | 1387.56 | | 国海证券股份有限公司南宁滨湖路证券营业部 | 1179.38 | | 国泰海通证券股份有限公司总部 | 1028.53 | （文章来源：证券时报网） 麦澜德1月6日龙虎榜 1月6日麦澜德（688273）收盘价61.22元，收盘涨停，全天换手率29.02%，振幅9.58%，成交额6.31亿 元。科创板交易公开信息显示，当日该股因日收盘价涨幅达15%等上榜。 证券时报·数 ...

Group 1 - The company focuses on providing medical gas equipment and systems, as well as medical clean equipment and systems for various medical institutions [1] - Medical gas and clean equipment systems are part of the smart hospital construction [1] - The company is paying continuous attention to the development of AI in healthcare, aiming to enhance the intelligence level of its products to meet the growing demands of modern hospital construction [1]

Financial Data and Key Metrics Changes - Revenue increased by 8.8% to $79.4 million, with Med Tech up 13% and Med Device up 5.6% [5][13] - Adjusted EBITDA nearly doubled year over year, reaching $5.9 million compared to $3.1 million in the previous year [5][22] - Gross margin improved to 56.4%, a 170 basis point increase from the previous year [20][19] Business Line Data and Key Metrics Changes - Med Tech revenue was $35.7 million, a 13% increase, contributing 45% of total revenue compared to 43% a year ago [14] - Auryon platform revenue grew 18.6% to $16.3 million, marking 18 consecutive quarters of double-digit growth [14][15] - Mechanical thrombectomy revenue increased by 3.9% to $11 million, with AlphaVac growing 40.2% to $3.5 million, while AngioVac revenue decreased by 7.5% to $7.5 million [15][16] Market Data and Key Metrics Changes - International sales for Auryon are beginning to contribute following CE Mark approval, with expectations for growth in the atherectomy market [6][58] - NanoKnife revenue increased by 22.2% to $7.3 million, driven by prostate procedures and a strong quarter for capital sales [17][10] Company Strategy and Development Direction - The company is focused on expanding its Med Tech segment, which addresses a $10 billion global market, and aims to increase penetration in hospitals [28] - Regulatory milestones for mechanical thrombectomy products are expected to enhance competitive positioning and expand clinical applications [8][9] - The company is committed to investing in R&D initiatives to support long-term growth, targeting approximately 10% of sales for R&D [21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to balance revenue growth with profitability, raising full-year guidance for revenue and adjusted EBITDA [5][24] - The company anticipates continued growth in the Med Tech segment and is optimistic about the long-term opportunities in mechanical thrombectomy and NanoKnife [10][42] Other Important Information - The company announced a leadership transition, with the current CEO planning to retire after a decade, and a search for a new CEO is underway [27][29] - A recent court ruling affirmed the invalidation of a competitor's patents, eliminating a potential $3 million payment [26] Q&A Session Summary Question: Comments on gross margin expectations - Management noted strong gross margin performance driven by positive pricing and a shift towards Med Tech sales, but structural underabsorption is expected in the second half due to manufacturing transitions [34][35] Question: Insights on mechanical thrombectomy performance - Management expressed satisfaction with AlphaVac's growth and acknowledged AngioVac's tough year-over-year comparison, but remains optimistic about its long-term potential [38][40] Question: Update on prostate procedures and CPT code changes - Management is monitoring the impact of the new CPT code on insurance coverage and expects it to be a catalyst for growth, particularly in the Medicare segment [48][50] Question: Adjusted EBITDA expectations for the third quarter - Management does not expect negative EBITDA in the third quarter but anticipates it will be lower than the first half due to planned investments [52][54] Question: Expectations for international sales and Auryon expansion - Management is optimistic about international sales growth following CE Mark approval and is focused on increasing awareness and adoption of Auryon [58][60]

Financial Data and Key Metrics Changes - Revenue increased by 8.8% to $79.4 million, with Med Tech up 13% and Med Device up 5.6% [12][5] - Adjusted EBITDA nearly doubled year-over-year to $5.9 million from $3.1 million [21] - Gross margin improved to 56.4%, a 170 basis point increase from the previous year [18] - Adjusted net loss reduced to $0.1 million, or an adjusted loss per share of $0.001, compared to a loss of $1.7 million or $0.04 per share last year [21] Business Line Data and Key Metrics Changes - Med Tech revenue was $35.7 million, a 13% increase, contributing 45% of total revenue [12][13] - Auryon platform revenue grew 18.6% to $16.3 million, marking 18 consecutive quarters of double-digit growth [13][14] - Mechanical thrombectomy revenue increased by 3.9% to $11 million, with AlphaVac growing 40.2% to $3.5 million, while AngioVac revenue decreased by 7.5% to $7.5 million [14][15] - NanoKnife revenue rose 22.2% to $7.3 million, driven by prostate procedures [16] Market Data and Key Metrics Changes - International sales for Auryon are beginning to contribute following CE Mark approval, with expectations for growth in the atherectomy market [6][44] - The company is targeting expansion into coronary applications, although significant R&D spending is not expected this year [46] Company Strategy and Development Direction - The company is focused on increasing penetration in hospitals and expanding its addressable market through various studies and regulatory approvals [6][8] - The leadership transition is underway, with the current CEO announcing retirement plans, which may impact strategic direction [26][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to balance revenue growth with profitability, raising full-year guidance for revenue and adjusted EBITDA [5][23] - The company anticipates continued growth in Med Tech and a slight increase in Med Device sales, with gross margin expected to remain stable [24][23] Other Important Information - The company received favorable court rulings regarding patent litigation, eliminating potential financial liabilities [25] - The transition to a distribution model in France is expected to enhance international sales and market presence [16] Q&A Session Summary Question: Comments on gross margin expectations - Management noted strong gross margin performance driven by positive pricing and product mix, but structural underabsorption is expected in the second half due to manufacturing transitions [31][33] Question: Insights on mechanical thrombectomy performance - Management highlighted strong growth in AlphaVac and expressed confidence in AngioVac's future growth despite a tough year-over-year comparison [34][35] Question: Update on prostate procedures and CPT code changes - Management is optimistic about the impact of the new CPT code on adoption rates, particularly in the Medicare market, and noted strong capital sales related to this [40][41] Question: Adjusted EBITDA expectations for the third quarter - Management expects positive EBITDA in the third quarter but not as robust as the first half due to planned investments [42] Question: International sales expectations for Auryon - Management is pleased with the uptake of Auryon internationally and anticipates gradual growth in sales as awareness increases [44]

智通财经APP讯，亚辉龙(688575.SH)发布关于自愿披露签署战略合作框架协议的补充公告，公告称： 深圳脑机星链科技有限公司(简称："脑机星链")成立时间短，规模较小，目前在睡眠产品方向主要开发 产品有脑电采集分析仪、脑机接口助眠仪、脑机接口睡眠监测仪、迷走神经刺激仪，相关产品尚未进入 注册申报阶段，其中，迷走神经刺激仪处于二类医疗器械证书注册检准备阶段;在阿尔茨海默症、孤独 症、脑卒中诊断领域相关产品目前尚处于早期研发阶段或临床前阶段。脑机星链目前在研产品的技术路 线为非侵入式技术路径，与马斯克创建的脑机接口公司Neuralink在技术路线上存在本质区别，目前也尚 无侵入式技术布局。 ...

每经AI快讯，1月6日，亚辉龙(688575.SH)发布自愿披露签署战略合作框架协议的补充公告称，脑机星 链成立时间短，规模较小，目前在睡眠产品方向主要开发产品有脑电采集分析仪、脑机接口助眠仪、脑 机接口睡眠监测仪、迷走神经刺激仪，相关产品尚未进入注册申报阶段，其中，迷走神经刺激仪处于二 类医疗器械证书注册检准备阶段；在阿尔茨海默症、孤独症、脑卒中诊断领域相关产品目前尚处于早期 研发阶段或临床前阶段。脑机星链目前在研产品的技术路线为非侵入式技术路径，与马斯克创建的脑机 接口公司Neuralink在技术路线上存在本质区别，目前也尚无侵入式技术布局。 ...

（编辑 袁冠琳） 证券日报网讯 1月6日，迈瑞医疗在互动平台回答投资者提问时表示，公司预计国内业务2026年全年有 望实现正增长，其中IVD将引领三大产线的增长，新兴业务将实现高速增长。同时，随着客户结构高端 化和产品结构流水化，2027年及之后国内业务的增速有望提高，并维持盈利水平稳定。以上内容不构成 业绩承诺，市场有风险，投资需谨慎。 ...

证券日报网讯1月6日，汉王科技（002362）在互动平台回答投资者提问时表示，公司的AI血压计是基 于公司在人工智能方面的技术能力创新研发出来的智能监测产品，也是公司进入大健康领域的一个切入 口；血压计属于国家二类医疗器械，对于公司来说是一个新的业务领域，公司需要在做好产品的基础 上，做好市场推广工作，快速适应和把握相关市场机会，在产品研发和销售推广端投入较大，也会面临 一定的市场不确定性。大健康领域是千亿级的市场，在做好做强AI血压计产品的基础上，公司也会关 注大健康领域的其他机会，跟踪产品和行业，如有合适的机遇，也会择机行动。 ...